Sacituzumab tirumotecan (sac-TMT; MK-2870/SKB264) generated a statistically significant and clinically meaningful improvement in overall survival (OS) vs treatment of physician’s choice in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least 2 prior lines of systemic therapy, meeting the primary end point of the phase 3 TroFuse-015 trial (NCT06356311).¹
However, sac-TMT did not meet the trial’s secondary end point of progression-free survival (PFS) assessed by blinded independent central review. The data are planned to be presented at a future medical conference and submitted to regulatory authorities.
At the final analysis, the OS benefit with sac-TMT was generally consistent across subgroups regardless of TROP2 expression status. Objective response rate (ORR), a secondary end point, showed a nominal improvement favoring sac-TMT over treatment of physician’s choice, although this end point was not formally tested under the prespecified analysis plan.
The safety profile of sac-TMT in TroFuse-015 was consistent with that observed in previously reported studies of the agent, and no new safety signals were identified.
TroFuse-015 Trial: Key Takeaways
- In TroFuse-015, sac-TMT produced a statistically significant and clinically meaningful OS improvement vs treatment of physician’s choice in patients with advanced gastroesophageal adenocarcinoma who had received at least 2 prior lines of therapy.
- Sac-TMT did not meet the trial’s secondary end point of PFS by blinded independent central review; ORR was nominally improved but not formally tested.
- The OS benefit was generally consistent across patient subgroups regardless of TROP2 expression, and no new safety signals were observed.
- The data are planned to be presented at an upcoming medical meeting and shared with regulatory authorities.
“Sac-TMT is the first TROP2[-directed] antibody-drug conjugate [ADC] to improve OS in a global phase 3 study in advanced gastroesophageal adenocarcinoma compared with treatment of physician’s choice, demonstrating its potential in a particularly challenging disease setting,” Marjorie Green, MD, senior vice president and head of oncology and global clinical development at Merck Research Laboratories, stated in a news release. “There is a tremendous unmet need for therapies that can improve survival for these patients. We look forward to discussing these data with regulatory authorities and sharing [them] with the scientific community on behalf of patients who may benefit.”
What was the rationale for evaluating sac-TMT in gastroesophageal adenocarcinoma?
Treatment options in the third-line setting and beyond are limited for patients with gastroesophageal adenocarcinoma.²
Sac-TMT is an investigational TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a bifunctional linker designed to maximize payload delivery to tumor cells and minimize payload loss in circulation throughout the body.¹
Previously, in the gastric/gastroesophageal junction (GEJ) cohort of the phase 1/2 KL264-01 trial (NCT04152499) presented at the 2024 AACR Annual Meeting, sac-TMT at 5 mg/kg every 2 weeks elicited responses, including in patients treated in the third-line setting or later.³
What was the design of TroFuse-015?
The randomized, open-label, multicenter, global trial enrolled 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least 2 prior lines of systemic therapy.¹ Eligible patients were at least 18 years; had measurable disease per RECIST 1.1 criteria by investigator assessment; had experienced disease progression after at least 2 prior lines of therapy, including a fluoropyrimidine and a platinum doublet; and had an ECOG performance status of 0 or 1.² Patients were eligible regardless of HER2 status, although those with HER2-positive disease needed to have previously received trastuzumab (Herceptin).⁴ Patients also needed to provide a tumor tissue sample for central TROP2 testing before random assignment. Key exclusion criteria included prior treatment with a TROP2-targeted ADC or a topoisomerase I inhibitor–based ADC or chemotherapy, known active central nervous system metastases or carcinomatous meningitis, grade 2 or higher peripheral neuropathy, or a history of noninfectious pneumonitis or interstitial lung disease that required steroids.²˒⁴